Stocks · Health care · Biological Products, (No Diagnostic Substances)

Gilead Sciences

GILD Clue Score57
United States Fiscal year ends December CIK 0000882095 Results filed 29 Oct 2026

What the insiders did Mostly scheduled

Insider
Date
Role
Action
Shares
Price
Amount
Kevin E Lofton
9 Mar 2023
Director
Exercised, kept
8,442
$52.38
$442.19K
Kevin E Lofton
28 Apr 2022
Director
Exercised, kept indirect
16,322
$25.63
$418.25K
Kevin E Lofton
22 Jan 2021
Director
Exercised, kept
20,282
$20.65
$418.72K
Kevin E Lofton
24 Feb 2020
Director
Exercised, kept
21,720
$19.63
$426.36K
Kevin E Lofton
24 Apr 2019
Director
Exercised, kept
13,208
$24.91
$328.95K
John F Milligan
27 Nov 2018
President and CEO
Exercised, kept
280,000
$23.60
$6.61M
John F Milligan
4 May 2018
President and CEO
Exercised, kept
80,000
$27.07
$2.17M
Showing 250 of 316 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 665
Amendments (4/A) skipped 2
Filings about a different issuer 15
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 95
Sales straight out of an exercise 187
Sales at will 26
Transactions with no price 0
Shares from compensation/vesting 9,649,606
Sales filed before the plan box existed 26
History held since 29 Sep 2006